Coverage
-
September 20, 2013
A putative class action lawsuit accusing GenVec Inc. of raising $26.2 million from shareholders to develop a pancreatic cancer treatment it knew to be ineffective was dismissed from a Maryland federal court on Friday, because the biopharmaceutical company never made material omissions.
1 other articles on this case.
View all »